Literatur
-
1
Schottmüller H.
Wesen und Behandlung der Sepsis.
Verh Dtsch Ges Inn Med.
1914;
31
257-261
-
2
Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee .
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
Crit Care Med.
1992;
20
864-874
-
3
Bruin-Buisson C, Doyon F, Carlet J.
Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units.
JAMA.
1995;
274
968-974
-
4
Wenzel R P.
Treating Sepsis.
N Engl J Med.
2002;
347
966-967
-
5
Wheeler A P, Bernard G R.
Treating patients with severe sepsis.
N Engl J Med.
1999;
340
207-214
-
6
Van den Berghe G, Wouters P, Weekers F. et al .
Intensive insulin therapy in critically ill patients.
N Engl J Med.
2001;
345
1359-1367
-
7
Warren B L, Eid A, Singer P. et al .
High-dose antithrombin III in severe sepsis a randomized controlled trial.
JAMA.
2001;
286
1869-1878
-
8
Bernard G R, Vinsent J L, Laterre P F. et al .
Efficacy and safety of human activated protein C for severe sepsis.
N Engl J Med.
2001;
344 (10)
699-709
-
9
Annane D, Sebille V, Charpentier C. et al .
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
JAMA.
2002;
288
862-871
-
10
Rivers E, Nguyen B, Havstad S. et al .
Early goal-directed therapy in the treatment of sepsis and septic shock.
N Engl J Med.
2001;
345
1368-1377
-
11
Hoffmann J N, Inthorn D, Jauch K-W.
Antiinflammatorische Therapie in der Sepsis.
Chirurg.
2003;
74
587-588
PD Dr. med. Johannes N. Hoffmann
Chirurgische Klinik u. Poliklinik Großhadern
Marchionistr. 15
81377 München
eMail: Johannes.Hoffmann@gch.med.uni-muenchen.de
